Dipeptidyl peptidase-4 inhibitor: Difference between revisions
Created page with "{{Short description|Enzyme blocker and diabetes treatment drug}} thumb|300px|right|DPP-4 inhibitors and GLP-1 '''Inhibitors of dipeptidyl peptidase 4''' ('''DPP-4 inhibitors''' or '''gliptins''') are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2. The first agent of the class – sitagliptin – w..." |
|||
| Line 12: | Line 12: | ||
==Examples== | ==Examples== | ||
Drugs belonging to this class are: | Drugs belonging to this class are: | ||
* [[Sitagliptin]] | * [[Sitagliptin]] (FDA approved 2006, marketed by [[Merck & Co.]] as [[Januvia]]) | ||
* [[Vildagliptin]] | * [[Vildagliptin]] (EU approved 2007, marketed in the EU by [[Novartis]] as Galvus) | ||
* [[Saxagliptin]] (FDA approved in 2009, marketed as [[Onglyza]]) | * [[Saxagliptin]] (FDA approved in 2009, marketed as [[Onglyza]]) | ||
* [[Linagliptin]] (FDA approved in 2011, marketed as Tradjenta by [[Eli Lilly and Company]] and [[Boehringer Ingelheim]]) | * [[Linagliptin]] (FDA approved in 2011, marketed as Tradjenta by [[Eli Lilly and Company]] and [[Boehringer Ingelheim]]) | ||
